Concentrated acidic component, kit for producing it, concentrated solution of acidic component for producing hemodialysis solution and method for producing it

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a concentrated acidic component for producing a hemodialysis solution. The acidic component contains the following ingredients in an amount of producing 1 litre of the solution in water purified for hemodialysis: 204.7-215.0 g of sodium chloride NaCl, 6.2-9.0 g of calcium chloride CaCl2*2H2O, 3.56-7.12 g of magnesium chloride MgCl2*6H2O, 5.22-10.44 g of potassium chloride KCl, 0.021-6.28 g of acetic acid and 0.02-6.2 g of succinic acid. Also, the invention refers to the hemodialysis solution containing the above concentrated acidic component, water purified for hemodialysis, and bicarbonate component. The invention also refers to a method for producing the hemodialysis solution with the method involving supplying the concentrated acidic component into a hemodialysis apparatus, diluting with water purified for hemodialysis, and mixing with bicarbonate component. What is also declared is a kit for producing the concentrated acidic component containing sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid in the form of dry agents and acetic acid in the form of a liquid agent.

EFFECT: invention provides higher effectiveness by a biochemical compatibility with blood plasma of the hemodialysis solution.

36 cl, 18 tbl, 16 ex

 

The technical FIELD

The invention relates to medicine, in particular to the compounds hemodialysis solutions for bicarbonate dialysis, which can be used in clinical practice in the conduct of extracorporeal blood purification to treat patients with acute and chronic renal failure.

The LEVEL of TECHNOLOGY

In the practice of hemodialysis traditionally used acetic acid (3-9 mmol/l), the concentration of which is many times greater than the physiological concentration in blood plasma (0.05 to 0.1 mmol/l), which causes patients acetami and a number of other adverse consequences. However, acetate is a natural and necessary substrate body: acetyl-coenzyme a is the main energy metabolite, located in the heart of pathways of carbohydrates, proteins and lipids.

Known acidic component for hemodialysis, including lactic, malic, citric, acetic acid [US 2010/055963, A1, 2010].

Known acid concentrate, including lactic, acetic, citric acid [US 6251437 B1, 03.12.2002]. However, in these inventions of different acids were used with the purpose of the pH Adjuster to reduce acetate ions in hemodialysis solution, prevent acetamide.

The disadvantages of the known substances should be attributed to the fact that the introduction of organic and not the content of inorganic fillers acid was directed at pH regulation, the concentration and ratio in hemodialysis solution was not optimized, and did not correlate with possible therapeutic effect, in the exercise of chronic hemodialysis.

Known hemodialysis solutions for bicarbonate hemodialysis [EN 2435567, 2011; RU 2311202, 2006; EN 2438663, 2010], which was reduced in patients acetami was observed and therapeutic effect in hemodialyzers solution of organic acids.

Hemodialyzers solution obtained by the method described in patent RU No. 2311202 contains the following components, mmol/l: sodium chloride NaCl 137,3-140,3, calcium chloride CAS2*2H2O 1,2-1,75, magnesium chloride MgCl2*6H2O 0,5-1,0, potassium chloride KCl 0,3-4,0, glucose (g/l) 1,0-5,0, sodium acetate to 0.3, citric acid 0,1-0,7, succinic acid C4H6O41,1-0,1. Hemodialyzers solution obtained by the method described in the patent of Russian Federation №2438663, 2010, contains the following components, mmol/l: sodium chloride NaCl 137,3-140,3, calcium chloride CaCl2*2H2O 1,2-1,75, magnesium chloride MgCl2*6H2O 0,5-1,0, potassium chloride KCl 0,3-4,0, glucose (g/l) 1,0-5,0, hydrochloric acid of 0.1 to 2.9, succinic acid C4H6O4of 0.1 to 2.9.

To the disadvantages of the known hemodialysis solutions obtained by the method described in patent RU №2311202, No. 2438663 is low biosovmestimostew with the patient's body due to its high osmolarity (318-328 mOsm/l), the above physiological osmolarity of human blood (280-310 mOsm/l). High osmolarity hemodialysis solutions obtained by the method described in these patents, due to high concentration in the known solutions of sodium and chlorine ions, and glucose, involved in maintaining the osmolarity hemodialysis solution and regulation of water-salt metabolism. Used solutions had a strong positive effect and lead to side effects in chronic dialysis treatment due to low biocompatibility. Patients from high blood pressure, have been deteriorating quality of life - thirst, itching and so on

Hemodialyzers solution obtained by the method described in patent RU 2435567 contains the following components, mmol/l: sodium chloride NaCl 137,3-140,3, calcium chloride CaCl2*2H2O 1,2-1,75, magnesium chloride MgCl2*6H2O 0,5-1,0, potassium chloride KCl 0,3-4,0, glucose (g/l) 1,0-5,0, acetic acid is 0.1 to 2.9, succinic acid C4H6C40,1-2,9, sodium bicarbonate 32,0.

Table 1 shows the qualitative and quantitative characteristics of the compositions described in examples 1-3 of the patent RU 2435567 taken as a prototype of the proposed method and hemodialysis solution for bicarbonate hemodialysis obtained from concentrated acid and bicarbonate components shall now, by dilution and subsequent mixing apparatus "artificial kidney".

Table 1
The name Jonah, mmol/lValues when using the compositions described in patent RU 2435567
example 1example 2example 3
Sodium chloride137,3140,3140,3
Calcium chloride1,21,751,75
Potassium chloride0,51,04,0
Magnesium chloride0,32,01,0
Chlorine105,8113,8114,5
Acetate0,12,92,2
Succinate 2,90,10,8
Citrate---
Hydrochloric acid---
Bicarbonate*323232
bicarbonate ions32
sodium ions35
Glucose, g/l*5,01,01,0
Theoretical osmolarity, mOsm/l318328339

To the disadvantages of the known hemodialysis solution obtained by the method described in patent RU 2435567 is low biocompatibility of solution to the patient's body due to its high osmolarity (318-328 mOsm/l), exceeding the physiological osmolarity of human blood (280-310 mOsm/l). High osmolarity hemodialysis solution, recip is spent on the way, described in patent RU 2435567 due to high concentration in the well-known solution of sodium and chlorine ions, and glucose, involved in maintaining the osmolarity hemodialysis solution and regulation of water-salt exchange.

The task, which sent a group of inventions is to create a new composition hemodialysis solution for bicarbonate hemodialysis, biocompatible with blood plasma containing a mixture of organic and inorganic acids, combines the functions of pH regulation and function of General metabolic effects on the body of the patient when conducting chronic hemodialysis.

The main problem is the same amount of organic acid in the dialysis solution, because the body must metabolize organic anion of the acid, the concentration of which is substantially greater than the physiological concentration in the blood plasma that when replacing one acid to another, for example, acetic acid to succinic acid, leads to complications, such acetamide. To solve this problem, we proposed to reduce the content of acetate into dialyzing solution due to the replacement of parts of acetic acid succinic acid. In order to additionally reduce the concentration of acetic and succinic acids to more optimal values part of acetic acid and tarnai acid was replaced by inorganic hydrochloric acid. Additional introduction in hemodialyzers the citric acid solution increases the efficiency of hemodialysis, due to the binding of calcium ions to prevent thrombosis of capillaries dialysator, the effectiveness of succinic acid increases.

Technical result achieved when using a group of inventions is to improve the effectiveness of dialysis by biochemical compatibility with blood plasma hemodialysis solution and optimization of its structure while enhancing therapeutic effect and the absence of side effects in the patient.

The achievement of the technical result is an optimally balanced qualitative quantitative composition of the components shown in the formula that helps to align the indicators osmolarity hemodialysis solution with indicators osmolarity of human blood plasma, providing high efficiency dialysis with receiving therapeutic effect.

Disclosure of inventions

To solve the problem and achieve the technical result of the proposed group of inventions, United by a common inventive concept.

One aspect of the invention is a concentrated acid component to obtain hemodialysis RA is down, including sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid and acetic acid, characterized in that the number of these components of the calculation to obtain 1 liter of a solution in purified for hemodialysis water, is:

sodium chloride NaCl204,7-215,0
calcium chloride CaCl2*2H2O6,2-9,0
magnesium chloride MgCl2*6H2O3,56-7,12
potassium chloride KCl5,22-10,44
acetic acid, C2H4O20,021-6,28
succinic acid C4H6O40,02-6,2

According to the invention a concentrated acid component further comprises citric acid C6H8O7from 0,022 to 7.3,

According to the invention a concentrated acid component further comprises hydrochloric acid HCl in an amount of from 0,012 to 3.8,

According to the invention the acid component further comprises glucose C6H12O6not more than 76,0,

With the according to the invention in a concentrated acid component total of all acid is 105 mEq/l

The next aspect of the invention is a concentrated solution of the acid component to obtain hemodialysis solution comprising sodium chloride, calcium chloride, magnesium chloride, potassium chloride, acetic acid, succinic acid in dissociated form in the following number, mEq/l:

sodium ions Na+3500,0-3675,0
calcium ions CA2+84,0-122,5
magnesium ions Mg2+5,0-70,0
potassium ions (K+70,0-140,0
chlorine ions Cl-3710,0-3937,5
acetate ions C2H3O2-0,35-104,65
succinate ions C4H4O42-0,35-104,65

According to the invention a concentrated solution of the acid component, optionally containing citric acid in dissociated form, where ions citratepresent in an amount of from 0.35 to 104,3 mEq/L.

According to the invention a concentrated solution of the acid to mponent further comprises hydrochloric acid in dissociated form, in which the content of chloride ions Cl-ranges from 0.35 to 104,3 mEq/L.

According to the invention a concentrated solution of the acid component further comprises glucose C6H12O6not more than 420 mmol/L.

According to the invention a concentrated solution of the acid component further comprises glucose6H12O6not more than 420 mmol/L.

According to the invention in a concentrated solution of the acid component to the total number of all acids is 105 mEq/l

Another aspect of the invention is hemodialyzable solution comprising a concentrated solution of the acid component, water purified for hemodialysis, or a concentrated solution of the acid component, water purified for hemodialysis, and bicarbonate component.

According to the invention hemodialyzers solution has the following composition, mEq/l:

sodium ions Na+135,0-140,0
calcium ions Ca2+2,4-3,5
magnesium ions Mg2+1,0-2,0
potassium ions (K+2,0-4,0
chlorine ions Cl-to 106.0-112,5
acetate ionsfrom 0.01 to 2.99
succinate ionsfrom 0.01 to 2.99
bicarbonate ions27,0-40,0

According to the invention hemodialyzers solution further contains citrate ionsin an amount of from 0.01 to 2,98 mEq/L.

According to the invention hemodialyzers solution further comprises chloride ions Cl-in an amount of from 0.01 to 2,98 mEq/l:

According to the invention hemodialyzers solution further contains glucose C6H12O6in an amount not greater than 12.0 mmol/L.

According to the invention hemodialyzers solution has the following composition, mEq/l:

sodium ions Na+138,0
calcium ions CA2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
yonehara Cl -109,5
acetate ions C2H3O2-0,3
succinate ions C4H4O42-0,7
ions of chlorine (hydrochloric acid)1,5
citrate ions0,5
bicarbonate ions HCO3-32,0

According to the invention hemodialyzers solution has the following composition, mEq/l:

sodium ions Na+138,0
calcium ions Ca2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions C2H3O2-0,3
succinate ions C4H4O42-0,8
ions of chlorine(hydrochloric acid) 1,4
citrate ions0,5
bicarbonate ions HCO3-32,0

According to the invention hemodialyzers solution has the following composition, mEq/l:

sodium ions Na+138,0
calcium ions Ca2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions C2H3O2-0,2
succinate ionsC4H4O42-1,0
ions of chlorine (hydrochloric acid)1,5
citrate ions0,3
bicarbonate ions HCO2-32,0

According to the invention hemodialyzers solution has the e following composition, mEq/l:

sodium ions Na+138,0
calcium ions Ca2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions C2H3O2-0,1
succinate ions C4H4O42-0,7
ions of chlorine (hydrochloric acid)1,2
citrate ions0,7
bicarbonate ions HCO3-32,0

According to the invention hemodialyzers solution may optionally include glucose in the amount of 5.5 mmol/L.

Another aspect of the invention is a method for hemodialysis solution according to any one of the compounds, including the flow of concentrated acid component according to the invention or a concentrated solution of the acid components is NTA according to the invention in an apparatus for hemodialysis, dilution with water, treated for hemodialysis, and mix with bicarbonate component.

According to the invention, hemodialyzers the solution obtained by the proposed method, has the following composition, mEq/l:

sodium ions Na+135,0-140,0
calcium ions Ca2+2,4-3,5
magnesium ions Mg2+1,0-2,0
potassium ions (K+2,0-4,0
chlorine ions Cl-to 106.0-112,5
acetate ions C2H3O2-from 0.01 to 2.99
succinate ions C4H4O42-from 0.01 to 2.99
bicarbonate ions HCO3-27,0-40,0

Another aspect of the invention is set to produce a concentrated acid component according to the invention or of a solution of concentrated acid component according to the invention, including sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid is in the form of dry reagents and acetic acid in the form of liquid reagent, characterized in that the number of these components of the calculation to obtain 1 liter of a solution in purified for hemodialysis water, is:

sodium chloride NaCl204,7-215,0
calcium chloride CaCl2*2H2O6,2-9,0
magnesium chloride MgCl2*6H2O3,56-7,12
potassium chloride KCl5,22-10,44
acetic acid, C2H4O20,021-6,28
succinic acid C4H6O40,02-6,2

According to the invention the kit further comprises citric acid C6H8O7from 0,022 to 7.3,

According to the invention the kit further comprises citric acid in the form of a dry reagent.

According to the invention the kit further comprises hydrochloric acid HCl in an amount of from 0,012 to 3.8,

According to the invention the kit further comprises hydrochloric acid in the form of liquid reagent.

According to the invention the kit further comprises glucose C6H12O6not more than 76,0 g/l

With the according to the invention in a set of dry reagents can be in the form of a mixture and/or in the form of a set of individual components.

Each receipt form concentrate from dry reagents or liquid can be made separately out of touch with the rest. Thus, the formation of a set of/a mixture of dry salts may lead to commercial set in which all components are dry, except those which under normal conditions cannot be represented by a dry substance, for example, acetic acid, hydrochloric acid.

Concentrated acid component can be obtained from such a set in the respective apparatuses, poured into containers for later use.

Hemodialyzers solution can be obtained by dilution of concentrated solutions using standard equipment, it is customary to make such concentrates which are subject to standard dilution. For example, an acid concentrate is mixed with purified for hemodialysis water apparatus "Artificial kidney" in the standard ratio of 1:35 or 1:44, although other schemes dilution.

The standard dilution of 1:35 assumes a: 1 l of liquid concentrated acid component A, 1,225 litres of 8.4% bicarbonate component B, 32,775 l treated for hemodialysis water.

A significant difference of the claimed group of inventions is optimized in accordance with the task, the concentrated composition to the PCI-e slot component, concentrated solution of the acid component, obtained by breeding treated for hemodialysis water to concentrate the acid component, hemodialysis solution obtained by diluting and mixing with bicarbonate solution, optimally balanced in accordance with the formula ratios of components on quantitative characteristics providing osmolarity input patient hemodialysis solution approximating the performance of the osmolarity of human blood plasma, the efficiency of the hemodialysis procedure while achieving therapeutic effect.

It is important to note that changes in the numerical values of sodium chloride in acidic component from 204.7 g/l to 215,0 g/l, and respectively of sodium ions in the concentrated solution from 3500 to 3675 mEq/l, and in hemodialysis solution from 135 mEq/l to 140 mEq/l; and changes in the numerical interval of glucose in the acid component, from 0 to 76 g (in dry form) and accordingly in concentrated hemodialysis solution from 0 to 420 mmol/l and diluted from 0 to 12 mmol/l balanced with the quantitative values of the other components, provides osmolarity input patient hemodialysis solution approximating indicators osmolarity is lazmi human blood.

Replacement parts acetic acid and/or succinic acid salt and/or citric acid and the balance between acids can further increase the efficiency of hemodialysis and get unexpected therapeutic effect without side effects in a patient.

The INVENTION

When bicarbonate hemodialysis uses two concentrated solution: acid component (A) and bicarbonate component (B), the solution of which can be replaced by bicarbonate cartridge containing dry reagent of sodium bicarbonate. Dilution and mixing of concentrates (A) and (B) and education hemodialysis solution occurs in the apparatus for hemodialysis (dialysis machine, the artificial kidney), which produces the fence concentrated components A and B with their subsequent dilution and mixing. Bicarbonate component contains sodium bicarbonate, which performs a buffer function blood to fill patients who are on hemodialysis. Typically, the concentrated bicarbonate component contains 84 g/l (1000 mEq/l) sodium bicarbonate NaHCO3. Modern artificial kidney" modes of operation are defined and set by the operator before the beginning of the session, depending on the patient's condition and may change throughout the process is of hemodializa. As for diluting concentrates using standard equipment, it is customary to make such concentrates which are subject to standard dilution. For example, an acid concentrate is mixed with water in hemodialysis apparatus in the standard ratio of 1:35, though other schemes dilution.

Depending on the clinical features of the patient's acid component may contain or not contain glucose. The stated acid component may contain glucose C6H12O6not more than 76,

The acid component must contain the acid to establish a pH after mixing the bicarbonate component in the range of from 7.3 to 7.4 for the purpose of preventing the deposition of calcium on the surface hemodialysis equipment. The input concentration of the acid or mixture of acids is usually 3 mEq/l in hemodialysis solution. "Acid component" and "Bicarbonate component, which are hemodialyzers solution for bicarbonate dialysis, can be in the form of concentrates (concentrate acid component, the bicarbonate concentrate component). After dilution of the acid concentrate "get diluted acid component.

For diluting concentrates used purified for hemodialysis water (demineralized the water).

Skills used chemical reagents for dissolution and subsequent dilution of concentrated solutions should be designed to meet hemodialysis solutions international, regional or national standards (Composition and Management of Hemodialysis Fluids.Pabst Science Publishers Lengerich, Berlin,Riga, Rom,Wien,Zagreb.p.l4). To obtain a therapeutic effect, for the purpose of conducting metabolic hemodialysis, by introducing into the solution of the organic acid is succinic, citric, leading to the intensification of the work of the Krebs cycle, traditionally a part of the acid component acetic acid is partially replaced by succinic acid.

The proposed composition of the acid component can optionally contain citric acid C6H8O7from 0,022 to 7.3, the Introduction of the citric acid solution improves the efficiency of dialysis, by preventing thrombosis fiber membrane, which in combination with succinic acid improves the quality of the dialysis procedure.

The proposed composition of the acid component may optionally also contain hydrochloric acid HCl in an amount of from 0,012 to 3.8, the Introduction of hydrochloric acid reduces the concentration of succinic, acetic and citric acids, the concentration of which is close to physiological, thereby increasing the BIOS is bestimate hemodialysis solution to the blood plasma, avoiding complications due to high concentrations of acids of the same name.

The total number of all acids in concentrated acid component is 105 mEq/l, which is essential for maintaining the pH of the solution.

Thus, the proposed preferred combination of acid addition results in a synergistic effect, demonstrating the advantage of the use of each acid separately. Reducing acidosis due to the replacement of parts of acetic acid to hydrochloric acid increases the efficiency of the hemodialysis procedure. Introduction to the composition of citric acid leads to increased efficiency effects on the body of the patient succinic acid.

The essence of invention is illustrated by examples in Table 2-17 summarizes qualitative and quantitative characteristics of dry and liquid concentrates acid component and based hemodialysis solution according to the invention. The data in Tables 2-17 provided to illustrate certain aspects of the implementation group of the inventions and are not intended to in any way limit the scope of the present group of inventions.

Example. 1

To obtain hemodialysis solution whose composition is given in Table 2, take the dry reagents in the amounts, set the built in graph 2, dissolved in purified for hemodialysis water and get concentrated hemodialyzers solution, the composition of which corresponds to the data shown in graph 3. Bicarbonate component take the form of concentrated 8,4% (1000 mEq/l) solution of sodium bicarbonate NaHCO3or it is prepared from the dry reagent (8.4 kg sodium bicarbonate) by dissolving purified for hemodialysis water. To obtain hemodialysis solution tank with a concentrated acid component and a container of concentrated bicarbonate component (in dry or liquid form) is connected to the hemodialysis apparatus in which the automatic mode is diluted in a predetermined ratio, for example, at a standard dilution of 1:35. When this acid component (A) is diluted in 35 times, bicarbonate component (B) of 28.6 times and mixes the components (A) and (B). Composition of dry and liquid concentrates and hemodialysis solution presented in table 2.

Table 2
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis dissolve the
Content, g/lContent, mEq/l
12345
Sodium chloride215,0Sodium ion3675,0140,0
Calcium chloride6,4Calcium ion87,52,5
Potassium chloride10,4Potassium ion140,04,0
Magnesium chloride3,6Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3937,5112,5
Acetic acid0,021Acetate is it 0,350,01
Succinic acid6,2Succinate ion104,652,99
Citric acid-Citrate--
Hydrochloric acid-Chlorine ion--
Glucose--
Sodium bicarbonate84,0The bicarbonate ion1000,032
Theoretical osmolarity, mOsm/l295

When mixed in WHEN diluted acid (A) and bicarbonate (B) component is a reaction of neutralization: 35 mEq/bicarbonate sodium 3 mEq of bicarbonate ions neutralized 3 mEq/l of hydrogen ions, but the solution remains 35 mEq/l of sodium ions. As a result, the content of sodium ions after mixing the components (A) and (B) is increased to 35 mEq/l, the composition hemodialysis solution will correspond to the composition shown in Table 2.

The resulting composition hemodialysis solution (hereinafter GDR) has an osmolarity equal to 295 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, which makes it more biocompatible with blood plasma and allows you to get therapeutic effect of the constituent hemodialysis solution of the mixture of acids.

Example 2

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing glucose (table 3).

Table 3
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
1 2345
Sodium chloride204,7Sodium ion3500,0135,0
Calcium chloride9,0Calcium ion122,53,5
Potassium chloride5,2Potassium ion70,02,0
Magnesium chloride7,12Magnesium ion70,02,0
Chlorine (salt)-Chlorine ion3762,5107,5
Acetic acid6,28The acetate ion104,652,99
Succinic acid0,02Succinate ion0,350,01
Citric acid-Citrate--
Hydrochloric acid-Chlorine ion--
Glucose35,0194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032
Theoretical osmolarity, mOsm/l290

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 290 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma and get in chronic dialysis treatment, therapeutic effect of the introduction of small amounts of succinic acid.

Example 3

Repeat getting hemodialysis solution of example 1, but is different from example 1 in the proportion of the components and optionally containing glucose (table 4).

Table 4
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride6,2Calcium ion84,02,4
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,0 1,0
Chlorine (salt)-Chlorine ion3846,5109,9
Acetic acid4,4The acetate ion74,22,12
Succinic acid1,8Succinate ion30,80,88
Citric acid-Citrate--
Hydrochloric acid-Chlorine ion--
Glucose35,0194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032
Theoretical osmolarity, mOsm/l 295,3

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal 295,3 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, and 30% replacement of acetic acid to succinic reduces the number of ions acetate and get in chronic dialysis treatment, therapeutic effect of the introduction of succinic acid.

Example 4

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing glucose (table 5).

Table 5
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
1234 5
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride7,8Calcium ion105,03,0
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3867,5110,5
Acetic acidthe 3.8The acetate ion63,01,8
Succinic acid2,5Succinate ion42,01,2
Citric acid -Citrate--
Hydrochloric acid-Chlorine ion--
Glucose35.0194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032
Theoretical osmolarity, mOsm/l296,5

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal 296,5 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, and 40% replacement of acetic acid to succinic can significantly reduce the number of ions acetate and get in chronic dialysis treatment, therapeutic effect of the introduction of succinic acid.

Example 5

Repeat getting hemodial youseo solution of example 1, but different from example 1 in the proportion of the components and optionally containing hydrochloric acid (table 6).

/tr>
Table 6
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride7,2Calcium ionfor 98.002,8
Potassium chloride10,44Potassium ion140,04,0
Magnesium chlorine is East of 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3878,0110,8
Acetic acid0,2The acetate ion0,350,01
Succinic acid1,4Succinate ion23,80,68
Citric acid-Citrate--
Hydrochloric acid0,29Chlorine ion80,52,3
Glucose
Sodium bicarbonate84,0The bicarbonate ion1000,032
Theoretical osmolarity, mOsm/l292

The resulting composition, WHEN containing a mixture of acids and having osmolarity equal to 292 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, and replacement of the acetic acid salt with the addition of small amounts of succinic acid can reduce the number of ions acetate 99,6% and get in chronic dialysis treatment, therapeutic effect of the removal of acetate ions and the introduction of small amounts of succinic acid.

Example 6

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing glucose, and hydrochloric acid (table 7).

Table 7
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis of rest the p
Content, g/lContent, mEq/l
12345
Sodium chloride215,0Sodium ion3675,0138,0
Calcium chloride7,2Calcium ionfor 98.003,0
Potassium chloride6,5Potassium ion87,52,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3832,5109,5
Acetic acid0,2The acetate ion0,351,49
Succinic acid0,02Succinate ion0,351,5
Citric acid-Citrate--
Hydrochloric acid0,012Chlorine ion0,350,01
Glucose35,0-194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l295

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 295 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, and replacement of 49.6%acetic key is lots to amber with the addition of 0.3% of succinic acid can reduce the number of ions acetate 50% and get in chronic dialysis treatment, therapeutic effect of the removal of acetate ions and the introduction of succinic acid.

Example 7

In a preferred embodiment of the invention repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing glucose, and hydrochloric acid (table 8).

Table 8
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride9,0Calcium ion122,53,5
Potassium chloride9,1 Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3885,0111,0
Acetic acid1.0The acetate ionof 17.50,5
Succinic acid2,1Succinate ion35,01,0
Citric acid-Citrate--
Hydrochloric acid1.9Chlorine ion52,51,5
Glucose35,0-194,25 mmol/l5,55 mmol/l
Bicarbonate is the atrium 84,0The bicarbonate ion1000,032
Theoretical osmolarity, mOsm/l297

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 297 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, hydrochloric, succinic acids in this embodiment, is preferred and allows you to get the most pronounced therapeutic effect of hemodialysis.

Example 8

In a preferred embodiment of the invention repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing hydrochloric acid (table 9).

Table 9
Name of indicatorA set of dry saltsName of indicator A concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride6,4Calcium ion87,52,5
Potassium chloride9,1Potassium ion122,53,5
Magnesium chloride4,6Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3850,0110,0
Acetic acid0,42The acetate ion 7,00,2
Succinic acid1,6Succinate ion28,00,8
Citric acid-Citrate--
Hydrochloric acid2,5Chlorine ion70,02,0
Glucose----
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l290

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 290 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemo is cialisinuaevo solution to the blood plasma, qualitative and quantitative mixture of acetic, hydrochloric, succinic acids in this embodiment, is preferred and allows you to get the most pronounced therapeutic effect of hemodialysis.

Example 9

In a preferred embodiment of the invention repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid and glucose (table 10).

Table 10
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chlorite is th 7,7Calcium ion1053,0
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3867,5110,5
Acetic acid0,2The acetate ion0,350,01
Succinic acid0,02Succinate ion0,350,01
Citric acid7,3Citrate104,32,98
Hydrochloric acid-Chlorine ion- -
Glucose35,0-194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l296

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 296 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of citric acid with a small addition of acetic, succinic acid allows its use for patients with intolerance to heparin in chronic dialysis treatment with therapeutic effect of the procedure.

Example 10

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid and glucose (table 11).

Table 11
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride7,7Calcium ion105,03,0
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (the salts) -Chlorine ion3867,5110,5
Acetic acid3,13The acetate ion52,151,49
Succinic acid3,1Succinate ion52,51,5
Citric acid0,02Citrate0,350,01
Hydrochloric acid-Chlorine ion--
Glucose35,0-194,25 mmol/l5,5 5 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l 297

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 297 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic acid with a small amount of citric acid compared to conventional dialysis leads to increasing the dose of dialysis, therapeutic effect of the hemodialysis procedure.

Example 11

In a preferred embodiment of the invention repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid (Table 12).

Table 12
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
1 2345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride9,0Calcium ion122.53,5
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3885,0111,0
Acetic acid2,7The acetate ion45,51,3
Succinic acid2,1Succinate ion35,01,0
Citric acid1,7Citrate24,50,7
Hydrochloric acid-Chlorine ion--
Glucose----
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l292

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 292 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic, citric acid compared with conventional dialysis leads to increased efficiency dialysis (increasing the dose of dialysis, relief reuse dialyzers) in the conjunction with therapeutic effect of the procedure.

Example 12

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid and glucose (table 13).

The bicarbonate ion
Table 13
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride6,2Calcium ion84,02,4
Potassium chloride5,22Potassium ion 70,02,0
Magnesium chloride3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3794,0108,4
Acetic acid2,1The acetate ion35,01,0
Succinic acid3.2Succinate ion35,01,5
Citric acid2,1Citrateof 17.50,5
Hydrochloric acid-Chlorine ion--
Glucose69,3-385,0 mmol/l11.0 mmol/l
Sodium bicarbonate84,01000,032,0
Theoretical osmolarity, mOsm/l298

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 298 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic, citric acid compared with conventional dialysis leads to increased efficiency dialysis (increasing the dose of dialysis, relief reuse dialyzers) in combination with therapeutic effect of the procedure. The addition of glucose prevents episodes of asymptomatic hypoglycemia in patients on chronic hemodialysis using metabolic dialysis, requiring significant amounts of glucose, in connection with the activity of the Krebs cycle.

Example 13

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid, hydrochloric acid and glucose (table 14).

Table 14
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride7,7Calcium ion105,03.0
Potassium chloride9.1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01.0
Chlorine (the salts) -Chlorine ion3867,5110,5
Acetic acid0,42The acetate ion7.00,2
Succinic acid2,07Succinate ion35,01,0
Citric acid0,74Citrate10,50,3
Hydrochloric acid1,9Chlorine ion52,51,5
Glucose35,0-194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/lthe 297

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 297 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic, citric acid, hydrochloric acid compared with conventional dialysis leads to increased efficiency dialysis (increasing the dose of dialysis, relief reuse dialyzers) in combination with therapeutic effect of the procedure. The introduction of hydrochloric acid in the amount of 50% significantly to bring the contents of organic acids to the physiological concentration in the blood plasma. The addition of glucose prevents episodes of asymptomatic hypoglycemia in patients on chronic hemodialysis using metabolic hemodialysis.

Example 14

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid, hydrochloric acid and glucose (table 15).

/tr>
Table 15
Name of indicator A set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride7,7Calcium ion105,03,0
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3867,5110,5
Acetic acid1,05The acetate ionof 17.50,5
Succinic acid1,6Succinate ion28,00,8
Citric acid0,5Citrate7,00,2
Hydrochloric acid1,9Chlorine ion52,51,5

12345
Glucose35,0-194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l 297

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 297 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic, citric acid compared with conventional dialysis leads to increased efficiency dialysis (increasing the dose of dialysis, relief reuse dialyzers) in combination with therapeutic effect of the procedure. The addition of glucose prevents episodes of asymptomatic hypoglycemia in patients on chronic hemodialysis using metabolic hemodialysis.

Example 15

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid, hydrochloric acid and glucose (table 16).

Table 16
Name of indicatorA set of dry saltsName of indicator A concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride9.0Calcium ion122,53,5
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3867,5110,5
Acetic acid2,1The acetate ion 35,01,0

12345
Succinic acid2,3Succinate iona 38.51,1
Citric acid1,7Citrate24,50,7
Hydrochloric acid0,25Chlorine ion7,00,2
Glucose35,0-194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l297

The resulting composition of the GDR, containing a mixture of acids and having osmolarity equal to 297 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic, citric acid, hydrochloric acid compared with conventional dialysis leads to increased efficiency dialysis (increasing the dose of dialysis, relief reuse dialyzers) in combination with therapeutic effect of the procedure. The addition of glucose prevents episodes of asymptomatic hypoglycemia in patients on chronic hemodialysis using metabolic hemodialysis.

Example 16

Repeat getting hemodialysis solution of example 1, but different from example 1 in the proportion of the components and optionally containing citric acid, hydrochloric acid and glucose (table 17).

Table 17
Name of indicatorA set of dry saltsName of indicatorA concentrated solutionDialysis solution
Content, g/lContent, mEq/l
12345
Sodium chloride210,9Sodium ion3605,0138,0
Calcium chloride9,0Calcium ion122,53,5

12345
Potassium chloride9,1Potassium ion122,53,5
Magnesium chlorideof 3.56Magnesium ion35,01,0
Chlorine (salt)-Chlorine ion3885,5111,0
Acetic acid2.7The acetate ion45,51,3
Succinic acid1,6Succinate ion28,00,8
Citric acid1,2Citrateof 17.50,5
Hydrochloric acid0.5Chlorine ion14,00,4
Glucose35,0-194,25 mmol/l5,55 mmol/l
Sodium bicarbonate84,0The bicarbonate ion1000,032,0
Theoretical osmolarity, mOsm/l297

The resulting composition of the GDR, containing a mixture of acids and having osmolarity, RA is Noah 297 mOsm/l, close in importance to the performance of the osmolarity of human blood plasma, can improve the biocompatibility hemodialysis solution to the blood plasma, qualitative and quantitative mixture of acetic, succinic, citric acid compared with conventional dialysis leads to increased efficiency dialysis (increasing the dose of dialysis, relief reuse dialyzers) in combination with therapeutic effect of the procedure. The addition of glucose prevents episodes of asymptomatic hypoglycemia in patients on chronic hemodialysis using metabolic hemodialysis.

In contrast to the GDR, obtained by the method described in the patent of Russian Federation №2435567, the rate of osmolarity-dependent content of all ions included in hemodialyzers solution, which is 318-339 mOsm/l (see table 1), indicators osmolarity of the proposed solution are in the range from 287 mOsm/l to 298 mOsm/l (see Table 2-17).

The achieved results osmolarity offer GDRs represent indicators osmolarity of human blood plasma, resulting in increased biochemical compatibility with the patient's body, which in turn allows to increase the efficiency of therapeutic effects of the injected part WHEN a mixture of organic and inorganic acids.

In the IP process the studies are installed, what is the effect of using hemodialysis compositions containing succinic acid depends on its concentration, which should be close to physiological. Acid introduced in the GDR, acts as a pH-regulator, the excess of which over 7.3 to 7.4 leads to loss of calcium-magnesium precipitation. In order to maintain the function of the pH Adjuster solution part of the acetic acid is replaced by hydrochloric acid, thereby reducing the concentration of acetic and succinic acids to the optimal values.

Introduction inorganic hydrochloric acid reduces the concentration of organic acids and the basic function of hemodialysis - removing toxins and translate in metabolic hemodialysis, i.e. to get various significant therapeutic effects.

In addition, as can be seen from examples 1-16, significantly reduced the quantitative interval of sodium ions from 135 mEq/l to 140 mEq/l in the GDR compared to the prototype (patent No. 2435567) 172,3-175,3 mmol/l Reduced the upper interval of glucose, which is also involved in osmolarity of the solution with 27,75 mmol/l (5 g/l in the prototype - patent RU 2435567) to 12 mmol/l, balanced with the quantitative values of the other components, provides osmolarity input patient hemodialysis solution approximating the performance of the osmolarity of human blood plasma.

For the tests of the action of the solutions conducted a crossover study with 2 groups of patients: control (n=40) and experienced (n=55). Both groups did not differ by age, gender, primary primary pathology, duration of hemodialysis treatment, the nature of comorbidity.

Within 6 months the control group received hemodialysis sessions using standard GDS with acetic acid, in the experimental group sessions were conducted using solutions according to the invention. The mode of dialysis therapy was similar in both groups (3 times a week for 4.5 hours), and hemodialysis sessions were conducted according to standard methods. 6 months after the commencement of the research was prescribed period "hillshade", during which both groups received therapy with hemodialysis using a standard solution. Then the groups were reversed, patients treated with sessions using GDS according to the invention remained on standard hemodialysis, the control group began to get the session using solutions according to the invention, this stage of the studies lasted 6 months.

According to the results of medical tests GDR according to the invention have the following effects from their use.

GDR containing a mixture of acids, have several advantages compared with standard bicarbonate hemodialysis.

Partial replacement of acetic acid amber for the first time allowed the dialysis procedure aimed at removing toxins from the body, make the AMB metabolic.

Succinic acid accelerates the turnover of dicarboxylic part of the Krebs cycle, increasing energy security cells, increases the consumption of oxygen by the tissues and improves tissue respiration.

First of all it should be noted that the cardioprotective effect contributes to the stabilization of angina, to reduce the frequency and duration of periods of myocardial ischemia, antiarrhythmic action.

In patients with chronic renal failure increased the level of glutamyltranspeptidase (GGT), which is exacerbated by concomitant liver diseases, chronic hepatitis, cardiovascular insufficiency (table 18).

Table 18
Indicators, unit of measureControl N=90The test group N=90Statistical significance (ANCOVA)
GGT (u/l)46.6±5.125.9±4.60.002

Established fact reduce the level of GGT in the blood plasma of patients receiving dialysis treatment with the GDR, containing a mixture of organic acids (succinic, citric) with inorganic (hydrochloric) acid, has a great CL the technical value since it was shown that the activity of GGT in the plasma is directly related to the risk of development of cardiovascular complications. Reduction of the level of GGT can be associated with the action of succinate as succinate stimulates the metabolic function of the liver while enhancing the stability of the membranes of hepatocytes to oxidative stress, and reduce the load on the liver acetate.

A very important result of the use dialysis solution containing the mixture of acids is phosphate-lowering effect. Hyperphosphatemia is associated with high mortality in patients on dialysis. Disorders of calcium and phosphorus metabolism varying degrees, are available in all patients with chronic kidney disease. In the process of metabolism of succinate is active consumption of inorganic phosphate. Succinyl-COA-synthetase, one of the key enzymes of metabolism of succinate, has the ability ecovalence to bind phosphate ion, which leads to increased activity of this enzyme, in turn, creates conditions for increasing the consumption of phosphate ion in the mitochondria. The level of phosphate contributes to the reduction of stress acetate, as is well known hyperphosphatemia action of high doses of acetate in acetate hemodialysis. To improve the efficiency of phosphate removal SPO is obstet adding citric acid in the GDR, which has anticoagulant effect by binding of calcium at the level of membrane dialysator. This leads to an increase in membrane permeability and increased transmission of other molecules through the membrane of dialysator, in particular anion succinic acid - succinate. The effectiveness of dialysis increases. Succinate in the composition of the dialysis solution reduces the degree of inhibition of oxidative processes in the Krebs cycle, increasing the intracellular accumulation of high energy compounds that can stimulate an increase in body weight and physical activity of patients. Succinate has insulinotropic effect, as a metabolic intermediary synthesis of proinsulin induced by glucose. The quality of life of patients is one of the most important criteria for the effectiveness of treatment. The action of succinate can explain the reduction of the manifestations of hypoxic encephalopathy. The mechanism of action of succinate can be associated with the participation of succinic acid in the synthesis of gamma-aminobutyric acid, one of the most important mediators of the nervous system.

A measure of physical functioning and summary measure of physical health are independent predictors of survival in hemodialysis patients. The results indicate positive changes in the quality of life of patients, which resulted in improving the Institute of physical and role-physical functioning; patients were less disturbed by various limits, decreased chest pain, joint pain, headaches, itchy skin, convulsions, sleep improved, significantly improved the patients ' ability to cope with physical stress. Improved quality of social interaction.

Introduction in the GDR citric acid increased the efficiency of hemodialysis, because due to the binding of calcium ions prevented the thrombosis of capillaries of dializador, the effectiveness of succinic acid increased. For shorter term indicators have improved the quality of life of the patient

Thus, the application of the GDR, containing a mixture of organic and inorganic acids, compared with the use of bicarbonate hemodialysis with acetic acid in patients on chronic hemodialysis leads to positive changes in several laboratory parameters, to improve the physical condition of patients, their health and quality of life.

1. Concentrated acid component to obtain hemodialysis solution comprising sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid and acetic acid, wherein the specified number of components of the calculation to obtain 1 liter of a solution in purified for hemodialysis water, is:

sodium chloride NaCl204,7-215,0
calcium chloride CaCl2*2H2O6,2-9,0
magnesium chloride MgCl2*6H2O3,56-7,12
potassium chloride KCl5,22-10,44
acetic acid2H4About20,021-6,28
succinic acid With4H6About40,02-6,2

2. Concentrated acid component under item 1, characterized in that it further comprises citric acid6H8O7from 0,022 to 7.3,

3. Concentrated acid component according to any one of paragraphs.1, 2, characterized in that it further comprises hydrochloric acid HCl in an amount of from 0,012 to 3.8,

4. Concentrated acid component according to any one of paragraphs.1, 2, characterized in that it further contains glucose6H12O6not more than 76,0,

5. Concentrated acid component under item 3, characterized in that it further contains glucose C6H12O6not more than 76,0,

6. Concentrated acid component according to any one of paragraphs.1, 2, characterized in that the total number of all acids is 105 mEq.

7. Concentrated acid component under item 3, characterized in that the total number of all acids is 105 mEq.

8. A concentrated solution of the acid component to obtain hemodialysis solution comprising sodium chloride, calcium chloride, magnesium chloride, potassium chloride, acetic acid, succinic acid in dissociated form in the following number, mEq/l:

sodium ions Na+3500,0-3675,0
calcium ions CA2+84,0-122,5
magnesium ions Mg2+35,0-70,0
potassium ions (K+5,22-140,0
chlorine ions Cl-3689,0-3937,5
acetate ions With2H3About2-0,35-104,65
succinate ions0,35-104,65

9. A concentrated solution of the acid component under item 8, optionally containing citric acid in dissociated form, where ions citratepresent in quantities is from 0.35 to 104,3 mEq/L.

10. A concentrated solution of the acid component according to any one of paragraphs.8, 9, additionally containing hydrochloric acid in dissociated form in which the content of chloride ions Cl-ranges from 0.35 to 104,3 mEq/L.

11. A concentrated solution of the acid component according to any one of paragraphs.8, 9, additionally containing glucose6H12O6not more than 420 mmol/L.

12. A concentrated solution of the acid component under item 10, optionally containing glucose6H12O6not more than 420 mmol/L.

13. A concentrated solution of the acid component according to any one of paragraphs.9, 10, in which the total number of all acids is 105 mEq/l

14. A concentrated solution of the acid component under item 10, in which the total number of all acids is 105 mEq/l

15. Hemodialyzers solution comprising a concentrated acid component according to any one of paragraphs.1-7, or a concentrated solution of the acid component according to any one of paragraphs.8-14, water purified for hemodialysis and bicarbonate component.

16. Hemodialyzers solution on p. 15, having the following composition, mEq/l:

sodium ions Na+135,0-140,0
calcium ions CA2+ 2,4-3,5
magnesium ions Mg2+1,0-2,0
potassium ions (K+2,0-4,0
chlorine ions Cl-105,4-112,5
acetate ionsfrom 0.01 to 2.99
succinate ionsfrom 0.01 to 2.99
bicarbonate ions27,0-40,0

17. Hemodialyzers solution according to any one of paragraphs.15, 16, optionally containing citrate ionsin an amount of from 0.01 to 2,98 mEq/L.
18 Hemodialyzers solution according to any one of paragraphs.15, 16, optionally containing chloride ions Cl-in an amount of from 0.01 to 2,98 mEq/L.

19. Hemodialyzers solution on p. 17, additionally containing chloride ions Cl-in an amount of from 0.01 to 2,98 mEq/L.

20. Hemodialyzers solution according to any one of paragraphs.15, 16, 19, optionally containing glucose6H12About6in an amount not greater than 12.0 mmol/L.

21. Hemodialyzers solution on p. 18, optionally containing glucose C6H12O6in an amount not greater than 12.0 mmol/L.

22. Hemodialyzers solution is on p. 15, having the following composition, mEq/l:

sodium ions Na+138,0
calcium ions CA2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions0,3
succinate ions0,7
ions of chlorine (hydrochloric acid)1,5
citrate ions0,5
bicarbonate ions32,0

23. Hemodialyzers solution on p. 15, having the following composition, mEq/l:

sodium ions Na+138,0
calcium ions CA2+3,5
Jonah is Agnes Mg 2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions0,3
succinate ions0,8
ions of chlorine (hydrochloric acid)1,4
citrate ions0,5
bicarbonate ions32,0

24. Hemodialyzers solution on p. 15, having the following composition, mEq/l:

sodium ions Na+138,0
calcium ions CA2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions 0,2
succinate ions1,0
ions of chlorine (hydrochloric acid)1,5
citrate ions0,3
bicarbonate ions32,0

25. Hemodialyzers solution on p. 15, having the following composition, mEq/l:

sodium ions Na+138,0
calcium ions CA2+3,5
magnesium ions Mg2+1,00
potassium ions (K+2,0
chlorine ions Cl-109,5
acetate ions0,1
succinate ions0,7
ions of chlorine (hydrochloric acid)1,2
citrate ions0,7
bicarbonate ions32,0

26. Hemodialyzers solution according to any one of paragraphs.22-25, additionally comprising glucose in the amount of 5.5 mmol/L.

27. The method of obtaining hemodialysis solution according to any one of any of paragraphs.15-26, including the flow of concentrated acid component according to any one of paragraphs.1-7 or concentrated solution of the acid component according to any one of paragraphs.8-14 in apparatus for dialysis, dilution with water, treated for hemodialysis, and mix with bicarbonate component.

28. The method according to p. 27, where the received hemodialyzers solution has the following composition, mEq/l:

sodium ions Na+135,0-140,0
calcium ions CA2+2,4-3,5
magnesium ions Mg2+1,0-2,0
potassium ions (K+2,0-4,0
chlorine ions Cl-105,4-112,5
acetate ionsfrom 0.01 to 2.99
succinate ionsbicarbonate ions27,0-40,0

29. Set to produce a concentrated acid component according to any one of paragraphs.1-7 or solution of concentrated acid component according to any one of paragraphs.8-14, including sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid in the form of dry reagents and acetic acid in the form of liquid reagent, wherein the specified number of components of the calculation to obtain 1 liter of a solution in purified for hemodialysis water is, g:

sodium chloride NaCl204,7-215,0
calcium chloride Cl2*2H2O6,2-9,0
magnesium chloride MgCl2*6H2O3,56-7,12
potassium chloride KCl5,22-10,44
acetic acid2H4About20,021-6,28
succinic acid With4H6About40,02-6,2

30. Set on p. 29, characterized in that it further comprises citric acid6H8Osub> 7from 0,022 to 7.3,

31. Set on p. 30 containing citric acid in the form of a dry reagent.

32. Set according to any one of paragraphs.29, 30, 31, characterized in that it further comprises hydrochloric acid HCl in an amount of from 0,012 to 3.8,

33. Set on p. 32 containing hydrochloric acid in the form of liquid reagent.

34. Set according to any one of paragraphs.29, 30, 31, characterized in that it further contains glucose6H12About6not more than 76,0 g/l

35. Set according to any one of paragraphs.32, 33, characterized in that it further contains glucose6H12About6not more than 76,0,

36. Set according to any one of paragraphs.29, 30, 31, 33 in which the dry reagents can be in the form of a mixture and/or in the form of a set of separate components.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a composition, adapted for intravenous introduction, intended for the treatment or prevention of pathological processes of crystallisation or calcification in a person, subjected to dialysis. The composition contains inositol phosphate and/or its pharmaceutically acceptable salt, with a dose of inositol phosphate and/or its salt constituting from 1 nmol/kg to 0.1 mil/kg. The invention also relates to a combined method of treatment, including the intravenous introduction of the said composition of the dialysis liquid simultaneously.

EFFECT: method is intended for the treatment or prevention of pathological processes, associated with an impairment of the regulation of physiologically adequate levels of inositol phosphate in blood plasma of the person, subjected to dialysis.

10 cl, 4 dwg, 1 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: what is declared is an infusion solution for filling the deficiency and meeting the physiological needs for water and basic electrolytes, which contains the following ingredients: sodium (Na+) - 27.72-28.28 mmole/l; fumarate(H2C4O42-) - 13.86-14.14 mmole/l; potassium (K+) - 18.61-18.99 mmole/l; calcium (Ca2+) - 3.56-3.64 mmole/l; magnesium (Mg2+) - 2.18-2.22 mmole/l; chlorine (Cl-) - 30.0-30.6 mmole/l; glucose (C6H12O6) - 189.1-192.9 mmole/l, water for injections.

EFFECT: solution contains the basic electrolyte concentration balanced for meeting the physiological needs; it is safe for the clinical application and can be used in diseases of various aetiology for patients of any age.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at intraoperative and early postoperative infusion therapy. A method involves administering a crystalloid balanced solution of sterofundin iso and a balanced colloidal solution of tetraspan. In the intraoperative period, sterofundin is administered with tetraspan in the volume ratio 3:1. In the early postoperative period, for the first day, sterofundin and tetraspan are administered in the volume ratio 6:1.

EFFECT: method is simple, safe, enables effectively correcting aqueous electrolyte disorders, stabilising systemic hemodynamic parameters, causing no negative effect on haemostasis and electrolyte composition of the blood serum.

1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a concentrated acid component for bicarbonate hemodialysis. The acid component includes sodium (Na+) in an amount of 2450.0-4550.0 mEq/l, chlorine (Cl-) in an amount of 2453.5-4553.5 mEq/l, hydrogen H+ (hydrochloric acid), succinate and citrate, each in an amount of 3.5-98.0 mEq/l. The invention also relates to a diluted acid component for bicarbonate hemodialysis, which includes sodium chloride 70.0-130.0 mEq/l, hydrochloric acid 0.1-2.8 mEq/l, succinic acid 0.1-2.8 mEq/l, and citric acid 0.1-2.8 mEq/l. The invention also relates to a concentrate for preparation of the acid component, which contains hydrochloric acid in a liquid form, and all other components in a dry form, as well as to a method of obtaining the acid component, which includes dissolution of dry chemical reagents from the said concentrate in water and addition of liquid reagents.

EFFECT: invention ensures obtaining a solution for dialysis, applied in case of acute and chronic renal failure.

14 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: before transfusion, a preserved blood sample of 2 ml is mixed with an ozonised solution of 0.9% sodium chloride with the ozone concentration of 2 mg/l in the equivalent volume. The 15-minute exposition is followed by evaluating the 2,3 diphosphoglycerate concentration in the prepared packed red cell suspension. The 2,3 diphosphoglycerate concentration in the packed red cell suspension more than 6 mcmole/l testifies to the high effectiveness of planned hemotransfusion.

EFFECT: using the invention provides higher accuracy of determining the suitability of the preserved packed red cells for transfusion that ensures higher clinical effectiveness in the severe patients by fast and stable correction of oxygen delivery and consumption preferentially by functionally adequate red cells.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a formulation of a perfluorinated blood substitute emulsion for biomedical applications, containing: perfluorinated hydrocarbons, emulsifying agents and an electrolyte solution differing by the fact that it contains a binary mixture of two perfluorinated hydrocarbons in ratio 1.55 to 1.99 in the concentration of 5 - 1000 g/l, with an average particle size of a perfluororganic compound of 25 - 250 nm; a binary mixture of the emulsifying agents in ratio 1.55 to 1.99 that are non-ionic block copolymers of ethylene oxide and propylene oxide - proxanoles: proxanole-268/proxanole-168; proxanole-268 in the concentration of 1 - 200 g/l with the molecular weight of 7 - 14 thousand Da; proxanole-168 in the concentration of 1 - 200 g/l with the molecular weight of 5 - 7 thousand Da; the electrolyte solution: NaH2PO4 - 0.18-0.25 g/l; NaCl - 5.5-6.5 g/l; and/or KCl - 0.37-0.41 g/l; and/or MgCl2 - 0.17-0.21 g/l; and/or NaHCO3 - 0.35-0.7 g/l; and/or glucose - 1.5-2.5 g/l.

EFFECT: invention ensures formulating the perfluorinated blood substitute with better aggregation and sedimentation stability and lower toxicity.

2 cl, 9 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, anesthesiology and intensive therapy, oncology, and can be applied in operations on account of non-organ retroperitoneal tumours. For this purpose prognostic criteria are determined on the basis of clinical and anamnestic parameters: Long stands for longitudinal dimension of tumour, in cm; Transv stands for transverse dimension of tumour, in cm; Rad stands for radical character of operation: 1 point means presence of radical intervention; 0 points means absence, palliative surgery, exploratory laparotomy; AddRes means carrying out additional resection of organs: 1 point means presence of organ resection; 0 points means operation only on tumour ablation; PorS stands for surgery on main vessels: 1 point stands for vascular plasty of arteries, resection of fragments of inferior vena cava, aorta; DifG stands for diffusion growth of tumour without capsulation: 1 point means presence; 0 points means absence. After that, coefficient of regression Z is calculated: Z=-0.581+0.038×Long+0.02×Transv+0.073×Rad+0.166×AddRes+0.133×PorS+0.102×DifG and substituted into formula: P1=11+e(1,24,18×Z) where e is base of natural logarithm with value e=2.72. If P1 constitutes from 0.87 to 0.26, massive intraoperative blood loss, requiring increased dose of colloids, but not more than 40 ml/kg/day in carrying out infusion therapy, is predicted.

EFFECT: method makes it possible to select optimal tactics of compensation of intravascular volume of colloids in operations in said category of patients due to more accurate calculation of blood loss volume.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to intensive therapy and narcology, and can be used in treatment of patients with frostbites, who are in the state of narcotic intoxication of different severity. For this purpose determined are: area of affection, degree of frostbite, degree of narcotic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(Cfs×S)+(Cn×MVDIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frostbite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV severity degree frostbite; S is area of affected surface, in cm2; Cn is coefficient of narcotic intoxication severity: 1.0 - in case of changed reactivity to narcotic substance; 1.5 - in case of psychic dependence (obsessive attraction); 2.0 - in case of physical dependence (compulsive attraction); 2.5 - in case of abstinence syndrome; MVDIT is minimal volume of disinfection infusion therapy in case of application of dezomorphin, equal to 1250 ml of infusion solutions per day; PN stands for physiological needs of organism during a day; PL stands for pathological loss during a day, constituting 500 ml in case of I and II degree of frostbites and 1000 ml in case of III and IV degree of frostbites.

EFFECT: method ensures adequate and differentiated performance of infusion therapy in said category of patients taking into account degree of narcotic intoxication, which contributes to prevention of "mutual aggravation", minimisation of disorders of hemostasis, microcirculation, as well as prevention of encephalopathy of complex genesis, including carrying out necrotomy and fasciotomy.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery and intensive therapy, and can be used in treatment of patients with frostbites. For this purpose degree of frost bite severity, area of affection, physiological needs of organism and pathological loss during a day are determined. After that, volume of infusion therapy is calculated by formula: V-C×S+PN+PL, where: V is volume of infusion therapy, in ml; C is coefficient of frost bite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV degree frostbites; S is the area of affected surface, in cm2; PN stands for physiological needs of organism during a day, in ml; PL stands for pathological loss during a day, in ml.

EFFECT: method ensures elimination of hemostasis and microcirculation disorders in pre-reactive period, as well as in early and late reactive periods due to carrying out adequate infusion therapy with optimal volume of solutions.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to narcology, and can be used in treatment of patients with frost bites, who are in the state of alcoholic intoxication of different severity. For this purpose determined are: degree of frostbite, area of affection, degree of alcoholic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(CfsxS)+(CfxSVIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frost bite severity: 1.0 in case of I and II degree frost bites; 2.0 in case of III-IV severity degree frost bite; S is area of affected surface, in cm2; Ca is coefficient of alcoholic intoxication severity: 0.5 in case of mild degree, 0.75 in case of medium severity; 1.0 in case of severe degree; 1.5 - in case of alcoholic coma; SVIT is standardised volume of infusion therapy, in case of alcoholic intoxication equal 2500 ml per day: PN stands for physiological needs of organism for a day, in ml; PL stands for pathological loss within a day, in case of I and II degree frost bites constituting 500 ml; in case of III and IV degree frost bites constituting 1000 ml.

EFFECT: method ensures adequate and differentiated carrying out infusion therapy in said category of patients, taking into account degree of alcoholic intoxication, which contributes to prevention of "mutual aggravation" syndrome, minimisation of hemostasis and microcirculation, as well as prevention of encephalopathy of complex genesis, alcoholic psychosis, including cases after carrying out necrotomy and fasciotomy.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely ophthalmology, and aims at treating cataract. A drug preparation for treating cataract based on the active substance sodium dihydroazapentacene polysulphonate (azapentacene) is presented in the form of ophthalmic drops. Stabilising is ensured by using a borate buffer and potassium chloride, a borate buffer and sodium chloride, a phosphate buffer, a quaternary ammonium derivative, Nipaging and a preserving agent of mercury derivatives. The ingredients are used in the declared amounts.

EFFECT: using the group of inventions provides the enhanced antimicrobial properties and the reduced toxicity of the ophthalmic drops, thereby increasing the clinical effectiveness in cataract.

6 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a new pharmaceutical composition in the form of spray for oral administration, containing an aqueous solution of sildenafil citrate as an active substance in the amount of 3-30 wt %. The composition contains stabilising agents in the form of pharmaceutically acceptable calcium salts taken in an amount required to reduce pH to 3.0 to 6.0. The calcium salts are specified in a group consisting of calcium lactate pentahydrate, calcium lactate trihydrate, calcium gluconate, calcium malate, calcium glycolate, calcium chloride hexahydrate and calcium chloride dihydrate. What is also described is a method for preparing the composition by introducing the pharmaceutically acceptable calcium salts as the stabilising agents into the aqueous solution of sildenafil citrate.

EFFECT: pharmaceutical composition in the form of oral spray is free from organic solvents and applicably for sexual dysfunction.

13 cl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention represents pharmaceutical composition for correction and therapy of manifestations of amyloid intoxication in patients with brain pathologies, which are characterised by the fact that it contains melatonin 3-10 mg and memantine 5-300 mg.

EFFECT: effective treatment of patients, including cases of moderate cognitive disorders.

4 cl, 2 ex, 6 tbl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a topical composition containing a combination of natural salt or pure sodium chloride and glucose mixed in ratio 1:1-30 (wt/wt) as an active ingredient in an amount effective for treating bacterial vaginosis caused by Cardnerella vaginalis together with a pharmaceutically acceptable carrier.

EFFECT: invention provides the higher pharmacological activity.

4 cl, 4 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: as active ingredients, a formulation contains fenoterol hydrobromide and ipratropium bromide monohydrate; the excipients are absolute ethanol, triethylcitrate, propellant 1,1,1,4 tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA-227ea) and a pharmaceutically acceptable acid specified in hydrochloric, orthophosphoric and citric acids.

EFFECT: increasing the respirable fraction and obtaining an optimised particle release profile.

2 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents method of treating prostate cancer, which includes introduction to patient of composition, which contains degarelix lyophilisate or its pharmaceutically acceptable salt and excipient, dissolved in solvent, in initial dose 200-300 mg of degarelix in concentration 20-80 mg of degarelix per ml of solvent with the following after 14-56 days after initial dose supporting dose 320-55 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, possibly with one or more than one following additional supporting dose 320-550 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, introduced with interval from 56 days to 112 days between each supporting dose.

EFFECT: invention provides long release of degarelix from obtained depot of medication without increase of occurrence of side effects.

11 cl, 1 ex, 2 dwg, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and represents a gel biologically active composition for topical application containing chitosan hydrochloride in an amount of 10-20 wt %, an organic acid in an amount of 1-10 wt %, distilled water - the rest. The above organic acid is specified in acetic, ascorbic, glycolic, lactic, citric or succinic acids.

EFFECT: providing a lower toxicity and a wider spectrum of biological action of the composition ensured by the synergetic effect of a reaction of chitosan hydrochloride and the organic acid.

11 ex, 11 tbl, 2 dwg

FIELD: chemistry.

SUBSTANCE: invention represents method of preparing viscoelastic protector of corneal endothelium, including dissolution of initial therapeutic component with excessive viscosity in phosphate buffer, filtration and sterilisation until required viscosity value is obtained, characterized by the fact that as initial therapeutic component used is 3% solution of native hyaluronic acid, after dissolution 1% peptide complex, consisting of amino acid desmosine and following short-chained peptides-oligopeptides: GlyTrpIle; IleAspIle; PheArgPro; GlnHisHis; ProHisTyr; ThrTrpTrp; LysPheThr; LysArgMet; PheCysMet; IleIle; AspLysLys; TrpPro; GluThr, is introduced, and sterilisation is carried out by ionizing radiation in the range of radioactive radiation from 78×107 Mrad to 11×108 Mrad.

EFFECT: recovery of biochemical processes in endothelial layer of cornea with constant eye cornea moistening and increase of biocompatibility, which contributes to fast rehabilitation after traumas or surgery.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a composition, adapted for intravenous introduction, intended for the treatment or prevention of pathological processes of crystallisation or calcification in a person, subjected to dialysis. The composition contains inositol phosphate and/or its pharmaceutically acceptable salt, with a dose of inositol phosphate and/or its salt constituting from 1 nmol/kg to 0.1 mil/kg. The invention also relates to a combined method of treatment, including the intravenous introduction of the said composition of the dialysis liquid simultaneously.

EFFECT: method is intended for the treatment or prevention of pathological processes, associated with an impairment of the regulation of physiologically adequate levels of inositol phosphate in blood plasma of the person, subjected to dialysis.

10 cl, 4 dwg, 1 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to an antibacterial composition and is intended for the oral cavity care. The antibacterial composition contains an antibacterial system, including a 4-isopropyl-3-methylphenol (IPMP) source of zinc ions and alkali metal C8-18 alkylsulphate and a perorally acceptable carrier or an excipient. The composition Ph constitutes from 5.5 to 7.5.

EFFECT: application of the invention provides the antimicrobial activity.

9 cl, 4 dwg, 3 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: method is characterised by the fact that 100 mg of iron sulphate of zinc sulphate are dissolved in 1 ml of water and obtained mixture is dispersed into solution of kappa-karrageenan in dioxane, which contains 300 mg of kappa-karrageenan, in presence of 0.01 g of E472c preparation with mixing. After that, 2 ml of methylcarbinol are poured in, obtained suspension is filtered and dried at room temperature, with realisation of the method without special equipment.

EFFECT: simplification and acceleration of the process of obtaining microcapsules and increased output by mass.

2 ex

Up!